Molecular Epidemiology of Respiratory Syncytial Virus during 2019–2022 and Surviving Genotypes after the COVID-19 Pandemic in Japan

Author:

Yoshioka Sayaka12,Phyu Wint Wint13ORCID,Wagatsuma Keita1,Nagai Takao4,Sano Yasuko5,Taniguchi Kiyosu6,Nagata Nobuo7,Tomimoto Kazuhiko8,Sato Isamu9,Kaji Harumi10,Sugata Ken6,Sugiura Katsumi6,Saito Naruo11,Aoki Satoshi12,Suzuki Eitaro13,Shimada Yasushi14,Hamabata Hirotsune15,Chon Irina1ORCID,Otoguro Teruhime2,Watanabe Hisami2,Saito Reiko12ORCID

Affiliation:

1. Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan

2. Infectious Diseases Research Center of Niigata University (IDRC), Niigata University, Niigata 951-8510, Japan

3. University of Medicine, Yangon, Myanmar

4. Nagai Pediatric Clinic, Takamatsu 760-0002, Japan

5. Sano Clinic, Niigata 950-0853, Japan

6. Mie National Hospital, Tsu 514-0125, Japan

7. Hiraoka-Kouen Pediatric Clinic, Sapporo 004-0872, Japan

8. Tomimoto Pediatric Clinic, Hachinohe 031-0823, Japan

9. Yoiko Pediatric Clinic Sato, Niigata 950-0983, Japan

10. Kaji Clinic, Hachioji 193-0816, Japan

11. Saito Pediatric Clinic, Moriyama 524-0022, Japan

12. Aoki Pediatrics, Kitakatsuragi 636-0002, Japan

13. Suzuki Pediatric Clinic, Ube 755-0151, Japan

14. Shimada Pediatrics, Kamiamakusa 869-3601, Japan

15. Awase Daiichi Clinic, Okinawa 904-2172, Japan

Abstract

To evaluate the changes in respiratory syncytial virus (RSV) collected between 2019 and 2022, we analyzed RSV-A and RSV-B strains from various prefectures in Japan before and after the COVID-19 pandemic. RT-PCR-positive samples collected from children with rapid test positivity at outpatient clinics in 11 prefectures in Japan were sequenced for the ectodomain of the G gene to determine the genotype. Time-aware phylogeographic analyses were performed using the second hypervariable region (HVR) of the G gene from 2012 to 2022. Of 967 samples, 739 (76.4%) were found to be RSV-positive using RT-PCR. RSV peaked in September 2019 but was not detected in 2020, except in Okinawa. Nationwide epidemics occurred with peaks in July 2021 and 2022. The genotype remained the same, ON1 for RSV-A and BA9 for RSV-B during 2019–2022. Phylogeographic analysis of HVR revealed that at least seven clusters of RSV-A had circulated previously but decreased to two clusters after the pandemic, whereas RSV-B had a single monophyletic cluster over the 10 years. Both RSV-A and RSV-B were transferred from Okinawa into other prefectures after the pandemic. The RSV epidemic was suppressed due to pandemic restrictions; however, pre-pandemic genotypes spread nationwide after the pandemic.

Funder

Health Labour Sciences Research Grant by the Ministry of Health, Labour and Welfare, and Sciences, Japan

Niigata Prefectural Medical Association

KAKENHI

MEXT

Japan Agency for Medical Research and Development

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Reference63 articles.

1. Respiratory syncytial virus and other respiratory viruses;Welliver;Pediatr. Infect. Dis. J.,2003

2. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis;Li;Lancet,2022

3. Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis;Shi;J. Infect. Dis.,2020

4. U.S. Food & Drug Administration (2023, September 05). FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine, Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine.

5. Pfizer (2023, September 05). U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults. Available online: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3